Abstract |
Twenty-one patients with hematopoietic malignancies including 6 previously untreated, 9 pretreated, and in relapse, 5 in complete remission and one in partial remission all were treated with PL-AC. The patients consisted of 12 acute myelocytic leukemias, 4 acute monocytic leukemias, 2 acute lymphocytic leukemias, one erythroleukemia, one malignant lymphoma and one chronic monocytic leukemia. PL-AC was given orally at a dosage of 50-1200 mg daily. Mean total dosage was 4.74 g (0.6-15.25), and the mean administration period was 3.43 days (1-122). days Responses were observed in 4 out of 9 pretreated patients by a decrease of blast cells in the peripheral blood. Partial remission was obtained in one case which lasted 8 months. Out of 5 previously untreated acute leukemias, one partial remission and 4 hematological responses were observed. The plasma concentration of Ara-C was maximal at 3 hours and was not detectable after 12 hours. Side effects observed were nausea in 5 patients vomiting in one patient and liver dysfunction in one patient. These side effects however were not so severe as to stop drug administration. PL-AC may be administered in doses ranged 150-250 mg for 2-3 weeks without any severe side effects, and with some clinical effects.
|
Authors | T Takubo, Y Kubota, T Tanaka, T Ueda, H Shibata, H Nakamura, T Masaoka, J Yoshitake, S Ishigami |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 10
Issue 2 Pt
Pg. 283-9
(Feb 1983)
ISSN: 0385-0684 [Print] Japan |
PMID | 6576729
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Cytarabine
- 5'-palmitoyl cytarabine
|
Topics |
- Administration, Oral
- Adolescent
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage, metabolism, therapeutic use)
- Child
- Cytarabine
(administration & dosage, analogs & derivatives, metabolism, therapeutic use)
- Drug Evaluation
- Female
- Humans
- Leukemia, Monocytic, Acute
(drug therapy)
- Leukemia, Myeloid, Acute
(drug therapy)
- Male
- Middle Aged
|